M344 (Synonyms: D237, Histone Deacetylase Inhibitor III, MS 344) |
Catalog No.GC16456
One-Click Copy Product Info
|
M344은 조톤 탈아세틸화효소(HDAC) 억제제로서 IC50 값이 100nM이다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 251456-60-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
M344은 조톤 탈아세틸화효소(HDAC) 억제제로서 IC50 값이 100nM이다. M344은 알츠하이머병 치료에 대한 가능성을 보여준다[2]. M344은 다양한 메커니즘을 통해 다양한 암세포 유형의 성장과 생존력을 효과적으로 억제한다[3-4].
체외 실험에서rAAV8 생산 중 형질도입 24시간 후 HEK293 세포에 M344(2.5–4μM)을 첨가하면 재조합 아데노연관바이러스의 게놈 역가가 현저하게 증가하였다[5]. 신경모세포종 세포 라인 SH-SY5Y, SK-N-BE(2), KP-N-NS를 M344(1μM)으로 12시간 처리하면 c-Jun 및 Fra-1의 mRNA와 단백질 발현 수준이 현저하게 억제되었고 인산화 활성도 감소하였다[6].
체내 실험에서 3개월령 알츠하이머병 모델 쥐에게 M344(3–10 mg/kg)을 주당 5일간 복강 내 투여한 결과는 4개월간 지속적으로 공간 기억과 인지 기능이 현저하게 개선되었다[7].
References:
[1] Zhu M, Han Y, Gu T, et al. Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway. Cell Rep. 2024 Apr 23;43(4):114065.
[2] Jeong H, Shin S, Lee JS, et al. Pan-HDAC Inhibitors Promote Tau Aggregation by Increasing the Level of Acetylated Tau. Int J Mol Sci. 2019 Sep 1;20(17):4283.
[3] Yeung A, Bhargava RK, Ahn R, et al. HDAC inhibitor M344 suppresses MCF-7 breast cancer cell proliferation. Biomed Pharmacother. 2012 Apr;66(3):232-6.
[4] Knoche SM, Brumfield GL, Goetz BT, et al. The histone deacetylase inhibitor M344 as a multifaceted therapy for pancreatic cancer. PLoS One. 2022 Sep 20;17(9):e0273518.
[5] Scarrott JM, Johari YB, Pohle TH, et al. Increased recombinant adeno-associated virus production by HEK293 cells using small molecule chemical additives. Biotechnol J. 2023 Mar;18(3):e2200450.
[6] He W, Wu Y, Tang X, et al. HDAC inhibitors suppress c-Jun/Fra-1-mediated proliferation through transcriptionally downregulating MKK7 and Raf1 in neuroblastoma cells. Oncotarget. 2016 Feb 9;7(6):6727-47.
[7] Volmar CH, Salah-Uddin H, Janczura KJ, et al. M344 promotes nonamyloidogenic amyloid precursor protein processing while normalizing Alzheimer's disease genes and improving memory. Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):E9135-E9144.
| 세포 실험 [1]: | |
세포 라인 | SH-SY5Y, SK-N-BE(2) 및 KP-N-NS 세포 (인간 신경모세포종 세포라인) |
제조 방법 | 세포는 10% 태아 소 혈청(FBS)을 보충한 DMEM 배지에서 유지 배양하였고 1μM 농도의 M344로 12시간 처리하였습니다. |
반응 조건 | 1μM; 12 시간 동안 |
응용 분야 | M344은 c-Jun과 Fra-1의 mRNA 및 단백질 발현 수준을 현저하게 억제해서 세포 성장을 억제하였고 MKK7의 단백질 및 mRNA 수준 모두에서 하향 조절을 유발하였습니다. |
| 동물 실험 [2]: | |
동물 모형 | 3 중 형질전환 알츠하이머병 (3xTg-AD) 쥐 (APPsw/PS1M146v/TauP301L) |
제조 방법 | 쥐는 3개월령(전증상 단계)부터 주 5일간 3 mg/kg 또는 10 mg/kg 용량의 M344을 복강 내 투여하였고 약 4개월 간 지속하였습니다. 처리 기간 종료 후 행동 시험을 실시하였습니다. |
제형 | 3 또는 10mg/kg;i.p.;약 4개월 동안 주 5일 |
응용 분야 | 만성 M344 처리는 인지 저하를 현저하게 방지하였습니다. 처리 그룹 쥐는 Y-maze 자발교체, 새로운 물체 인식 및 Barnes maze 공간 기억 테스트에서 용매 대조 그룹에 비해 성능이 향상되었습니다. M344 처리는 해마 내 Aβ1-42 수준과 Ser396 부위 타우에서 인산화를 현저하게 감소시켰고 해마 ADAM10 유전자 발현을 증가시켰습니다. |
References: | |
| Cas No. | 251456-60-7 | SDF | |
| Synonyms | D237, Histone Deacetylase Inhibitor III, MS 344 | ||
| Chemical Name | 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide | ||
| Canonical SMILES | CN(C)C1=CC=C(C=C1)C(=O)NCCCCCCC(=O)NO | ||
| Formula | C16H25N3O3 | M.Wt | 307.39 |
| Solubility | ≥ 14.75 mg/mL in DMSO, ≥ 12.88 mg/mL in EtOH with ultrasonic | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.2532 mL | 16.266 mL | 32.532 mL |
| 5 mM | 650.6 μL | 3.2532 mL | 6.5064 mL |
| 10 mM | 325.3 μL | 1.6266 mL | 3.2532 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)